Although less common than the evolution of antimicrobial drug resistance, vaccine resistance can and has evolved. How likely is it that COVID-19 vaccines currently in development will be undermined by viral evolution? We argue that this can be determined by repurposing samples that are already being collected as part of clinical trials. Such information would be useful for prioritizing investment among candidate vaccines and maximizing the potential long-term impact of COVID-19 vaccines. Will a safe and efficacious COVID-19 vaccine be undermined by vaccine-resistance evolution? Rather than take a wait-and-see approach, this Perspective article argues that this question can be answered even before a vaccine is licensed, by repurposing samples already being collected in clinical trials.
【초록키워드】 Evolution, Vaccine, COVID-19 vaccine, clinical trials, COVID-19 vaccines, drug resistance, information, Safe, candidate vaccine, approach, collected, less, question, 【제목키워드】 Evolution, COVID-19 vaccine, clinical trial,